Bregal Milestone Announces Strategic Growth Investment in Ridango
19.3.2025 15:41:00 CET | Business Wire | Press release
Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in Ridango, a global provider of mission-critical public transportation software. The investment is made in partnership with founder Erki Lipre and the Ridango management team. Terms of the transaction were not disclosed.
Founded in 2009, Ridango is a global market leader in intelligent transportation software for public transport authorities, municipalities, cities, and private transport operators. Ridango has built one of the world’s leading integrated automated fare collection and operations control software platforms, serving more than 150 customers in over 25 countries across five continents. The Company’s modern software provides end-to-end transit management services, from account-based ticketing to contactless bank card acceptance, real-time passenger information, and automatic vehicle location operations management to deliver better transit services, more accurate real-time visibility, and improved passenger satisfaction.
With operational and financial support from Bregal Milestone, Ridango aims to accelerate its organic and inorganic growth. Following accelerated customer activity in Sweden, including customer wins from Västtrafik, Sörmlandstrafiken, and Västmanlandstrafiken, the Company will operate from its new European headquarters in Sweden; its R&D hubs in Estonia and Slovenia; and its regional sales and marketing hubs following major customer wins in the Middle East (UAE, Qatar, and Saudi Arabia) and APAC (Singapore and Hong Kong).
“Our partnership with Bregal Milestone marks a significant next step in our growth strategy. We extend our sincerest thanks to our prior investors, BaltCap Private Equity, and look forward to the proactive support and expertise from Bregal Milestone and their in-house value creation team, Milestone Performance Partners, to help accelerate our investment in next-generation technology and accelerate our GTM activity in new markets,” said Erki Lipre, Founder and CEO of Ridango. "Public transportation is at the heart of sustainable urban development, and the team at Ridango is tirelessly committed to delivering the most advanced solutions to help modernize transit networks for the future."
“Ridango’s strong commitment to innovation has positioned it as a software operating system of choice for transit operators looking to modernize fare collection and optimize passenger experience,” added Cyrus Shey, Managing Partner at Bregal Milestone. “We see strong secular tailwinds as private transport operators and public rail and mass transport operators accelerate investments in digitalization, underpinned by the accelerated shift from card-based ticketing to account-based ticketing systems, and we are thrilled to partner with Erki and his leadership team to support Ridango in capitalizing on these megatrends.”
Sebastian Charpentier, Principal at Bregal Milestone, adds, “We are honored to enter this strategic partnership with Ridango, a company that continues to drive innovation and deliver customer service with what we see as the most advanced end-to-end transit software offerings featuring AI-driven predictive analytics and cloud-based fare collection. We believe that Ridango is uniquely positioned to lead the digital transformation for public transportation authorities and operators alike, creating sustainable long-term value for the communities in which they operate.”
White & Case served as legal counsel and Deloitte as financial advisor for Bregal Milestone. Sorainen served as legal counsel for Ridango.
The transaction will be closed after necessary regulatory approvals have been obtained.
About Bregal Milestone
Bregal Milestone is a leading software and technology private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €19 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2024. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Ridango
Ridango is the software operating system of choice for public transportation providers globally, specializing in automated fare collection (“AFC”), real-time passenger information systems, automatic vehicle location tracking (“AVL”), and mobility-as-a-service (“MaaS”) technology. The company partners with transport authorities and operators to enhance the efficiency, accessibility, and sustainability of public transit for customers and operators alike.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319073578/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom